Direct Reprogramming of Fibroblasts to Cardiomyocytes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively regenerate damaged heart tissue after myocardial infarction, leading to persistent scar tissue and diminished heart function, highlighting a need for new strategies to convert fibrotic tissue into functional cardiomyocytes.
Innovation Solution
The use of microRNA oligonucleotides or combinations thereof, along with small molecules, to directly reprogram cardiac fibroblasts or other differentiated cells into cardiomyocytes or cardiomyocyte progenitors, either in vivo or ex vivo, without an intermediate stem cell phenotype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to treat myocardial infarction, then heart tissue is repaired, but the repaired tissue forms non-functional scar tissue rather than regenerating functional cardiomyocytes
Solution Approach 1:
The patent changes the biological state parameters of fibroblasts by introducing specific microRNAs (miR-1, miR-133a, miR-206, miR-208a) that reprogram gene expression profiles, transforming the cellular phenotype from fibrotic to cardiomyocytic. This parameter change in gene expression enables functional recovery by generating contractile cardiomyocytes instead of non-functional scar tissue.
Solution Approach 2:
The patent uses microRNA molecules as intermediary agents to mediate the transformation of fibroblasts into cardiomyocytes. These microRNAs act as molecular mediators that regulate gene expression networks, activating cardiomyocyte-specific programs and suppressing fibrotic pathways, thereby enabling functional tissue regeneration.
2Reliability
If fibroblasts are directly reprogrammed to cardiomyocytes using microRNA oligonucleotides, then functional cardiomyocytes are generated, but the complexity of the reprogramming process increases
Solution Approach 1:
The patent segments the reprogramming process into distinct components: specific microRNA oligonucleotides (miR-1, miR-133a, miR-206, miR-208a) are individually designed and combined in defined ratios. Each microRNA targets specific gene networks, and their combined effect achieves comprehensive reprogramming. This segmentation allows systematic optimization of each component's contribution to the overall regeneration process.
3Reliability
If scar tissue is replaced with regenerated cardiomyocytes, then heart function is restored, but the time required for effective treatment increases
Solution Approach 1:
The patent employs preliminary action by pre-designing and pre-combining specific microRNA oligonucleotide sequences that are optimized for direct reprogramming activity. The microRNA combinations are prepared in advance with defined concentrations and delivery mechanisms, enabling immediate upon administration to initiate the reprogramming cascade without requiring sequential optimization steps during treatment.
Data Source
AI summary
A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.